Tempus AI, Inc. Class A Common Stock
TEMTempus AI, Inc. Class A (TEM) is a technology company focused on developing artificial intelligence-driven solutions. It specializes in leveraging AI to improve efficiency and decision-making in various industries, including finance, healthcare, and enterprise services. The company aims to deliver innovative software and data analytics tools to enhance business operations and insights.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 28, 2006 | $0.26 | 2006-07-18 | 2006-07-20 |
| July 28, 2006 | $0.44 | 2006-07-18 | 2006-07-20 |
| June 22, 2005 | $0.23 | 2005-06-10 | 2005-06-14 |
| June 28, 2004 | $0.22 | 2004-06-21 | 2004-06-23 |
| June 26, 2003 | $0.20 | 2003-06-16 | 2003-06-18 |
Dividends Summary
- Tempus AI, Inc. Class A Common Stock has issued 5 dividend payments over the past 3 years
- The most recent dividend was paid 7073 days ago, on July 28, 2006
- The highest dividend payed out to investors during this period was $0.44 per share
- The average dividend paid during this period was $0.27 per share.
Company News
Tempus AI is a healthcare AI company with over 400 petabytes of medical data and partnerships with top oncology companies. Despite strong revenue growth of 85%, the company continues to struggle with profitability and high cash burn, making it a risky investment.
The global physical AI market is projected to grow from $4.12 billion in 2024 to $61.19 billion by 2034, with a 31.26% CAGR, driven by advances in robotics, AI-enabled surgery, and automation across healthcare, manufacturing, and logistics sectors.
Tempus AI reported strong Q3 performance with 85% revenue growth, achieving first positive EBITDA quarter and raising year-end guidance. Despite stock price pullback, analysts see potential upside and value in the AI genomics and oncology data services company.
Tempus AI reported Q3 FY25 earnings beating analyst estimates, with revenue of $334.21 million and raised full-year guidance. An analyst expects growth from higher-priced tests and expanding pharma contracts.
